ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-PO033

Antithrombin III Is a Novel Predictor for Contrast Induced Nephropathy after Coronary Angiography: An Observational, Cross-Sectional Study

Session Information

Category: Acute Kidney Injury

  • 003 AKI: Clinical and Translational

Authors

  • Yin, Jianyong, Department of Nephrology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China
  • Wang, Feng, Department of Nephrology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China
  • Wang, Niansong, Department of Nephrology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China
Background

Antithrombin III (AT-III) functions as an important endogenous anticoagulant and has powerful anti-inflammatory effects. Low AT-III activity is considered to be a predictor of poor outcomes in several conditions, including acute kidney injury after cardiac surgery. However, whether the AT-III levels are related to the incidence of contrast induced nephropathy(CIN) has not been identified yet.

Methods

A cross-sectional study on CIN after CAG was conducted to identify the potential predictive value of AT-III for CIN. A total of 460 patients who underwent coronary angiography(CAG) from January 2015 to December 2016 in coronary care units(CCU) were enrolled. CIN was diagnosed according to the KDIGO guideline. Plasma AT-III activity was measured before CAG and <75% was recognized as low activity according to reference values.

Results

Of 460 patients undergoing CAG, 125(27.17%) developed CIN. The incidence of CIN was significantly higher in patients with low AT-III activities than that in normal group (Pearson’s chi-squared test P=0.002). Besides, with the decline of AT-III activity, the prevalence of CIN progressively rise, with the highest value(58.8%) in patients with AT-III activity<60%. Moreover, the AT-III activity was significantly lower in CIN patients than that in non-CIN ones(84.43±16.3% vs. 92.14±13.94%,P<0.001). After multivariable analysis, low AT-III activity remained a significant independent predictor of CIN(OR 2.207,95%CI[1.29-3.777];P=0.004) as well as baseline serum creatinine(OR 1.009,95%CI[1.001-1.016];P=0.026).

Conclusion

Patients with low AT-III activities presented a higher risk of developing CIN after CAG. And the initial AT-III activity may be an independent predictor for CIN.

Funding

  • Government Support - Non-U.S.